Back to Health Guide
Patient Education1 min read

Ustekinumab (Stelara)

From the هضم DIGEST medical team · GI, liver and endoscopy · Riyadh

Ustekinumab (Stelara)

Overview

Ustekinumab is a biologic that targets interleukins IL-12 and IL-23 — key cytokines in the inflammatory cascade of Crohn's disease and ulcerative colitis. It is given as a single intravenous dose for induction, then as subcutaneous injections for maintenance every 8 or 12 weeks.

Key Uses

1

Moderate-to-severe Crohn's disease (including after anti-TNF failure)

2

Moderate-to-severe ulcerative colitis

3

Also approved for plaque psoriasis and psoriatic arthritis

How It Works

•

Binds the p40 subunit shared by IL-12 and IL-23, blocking their pro-inflammatory signalling

•

Reduces Th1 and Th17 immune cell activity — key drivers of IBD inflammation

•

Induction: single weight-based IV infusion; maintenance: 90 mg SC every 8 or 12 weeks

•

Favourable safety profile — one of the lowest infection rates among IBD biologics

Safety & Self-Care

TB and hepatitis B screening before starting

Generally well tolerated — injection site reactions and mild upper respiratory infections are most common side effects

Avoid live vaccines; keep inactivated vaccines current

Self-injection can be learned at the clinic — training is provided

Store pre-filled syringes in the refrigerator; allow to reach room temperature before injecting

Contact Your IMCC Team

Contact your IMCC team if symptoms flare between doses, you develop infection signs, or if you are planning pregnancy or any surgical procedure.

What ustekinumab is and how it is given

Ustekinumab is a biologic that blocks interleukins 12 and 23, two proteins involved in the immune inflammation seen in Crohn's disease and ulcerative colitis. It is also used for psoriasis and psoriatic arthritis. For bowel disease it is usually started with a single intravenous infusion, followed by injections under the skin that are repeated every eight to twelve weeks, so the injections are infrequent. Biosimilar versions are now available. It is prescribed by a specialist, who decides the schedule.

Side effects, safety and monitoring

Ustekinumab is usually well tolerated. Common effects are colds and upper respiratory infections, headache, tiredness and injection-site redness. As with other immune-targeting drugs, infections are the main concern, and you are screened for tuberculosis and hepatitis B first. Rare effects include serious infections and allergic reactions. Skin changes should be checked during treatment, and live vaccines should be avoided. Your specialist will review your symptoms, blood tests and stool inflammation markers to check that it is working.

Frequently Asked Questions

What is ustekinumab used for?
Moderate to severe Crohn's disease and ulcerative colitis, and also plaque psoriasis and psoriatic arthritis.
How often is ustekinumab injected?
After a first infusion into a vein, injections under the skin are usually given every eight to twelve weeks. The exact interval is decided by your specialist.
What are the side effects of ustekinumab?
Colds and upper respiratory infections, headache, tiredness and injection-site reactions are common. Serious infections and allergic reactions are rare.
Can ustekinumab be stopped if I am in remission?
Stopping often leads to relapse, so any decision to stop or space out the injections should be made with your specialist and follow-up tests.

Share this with someone who needs it:

Have questions or need a consultation?

Our GI specialists are ready to help you

Same-week appointments · WhatsApp replies during working hours